- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06601569
Predictors of Range of Motion and Balance Abnormalities in Children Diagnosed with Cerebral Palsy
September 29, 2024 updated by: Ahmed fekry ibrahim salman, Cairo University
- To better understand the factors that contribute to ROM abnormalities in children diagnosed with CP.
- To describe the distribution of primary (muscle tone and postural stability)and secondary impairments (ROM and functional muscle strength) across the gross motor spectrum measured by GMFCS scores.
- To evaluate the effects of primary and secondary impairments on gross functional outcome in children with spastic CP.
- To find any possible correlation between clinical variables.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: ahmed fekry salman
- Phone Number: +201067873174
- Email: a.salman@ammanu.edu.jo
Study Locations
-
-
-
Cairo, Egypt
- Recruiting
- Faculty of Physical Therapy Cairo University
-
Contact:
- mahmoud usama
- Phone Number: +21285221209
- Email: afekry335@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
children with cerebral plasy their age ranged fro 18 month t 5 yeas old
Description
Inclusion Criteria:
- only children with clinical diagnosis of cerebral palsy , who were receiving physiotherapy services at the paediatric out-patient clinic of Faculty of Physical Therapy, Cairo University for a minimum of six months regularly.
Exclusion Criteria:
- Children were excluded if they had one or more of the following: behavioral issues, a history of persistent heart or chest disease, significant visual or auditory impairment, botulinum toxin injection at last six months prior to the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
diplegic cerebral palsy
|
Other Names:
|
|
quadripledic cerebral palsy
|
Other Names:
|
|
hemiplegic cerebral palsy
|
Other Names:
|
|
dyskinetic cerebral palsy
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
predictors of range of motion and balance abnormalities
Time Frame: from 1 august 2024 to 1 october 2024
|
the aim of the study is to investigate the predicted cause if the range of motion abnormalities measured by (spinal alignment and range of motion assessment scale ) and balance abnormalities ( measured by early clinical assessment of balance scale )in children with cerebral palsy like muscle strength (measured by functional muscle strength scale) and muscle tone changes (measured by modified athwart scale)
|
from 1 august 2024 to 1 october 2024
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2024
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
July 27, 2024
First Submitted That Met QC Criteria
September 15, 2024
First Posted (Actual)
September 19, 2024
Study Record Updates
Last Update Posted (Actual)
October 1, 2024
Last Update Submitted That Met QC Criteria
September 29, 2024
Last Verified
September 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P.T.REC/012/005209
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.